We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GERN Geron Corp

0.07 (3.63%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 4,091,654
Bid Price 1.99
Ask Price 2.00
News -
Day High 1.995


52 Week Range


Day Low 1.87
Share Name Share Symbol Market Stock Type
Geron Corp GERN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.07 3.63% 2.00 18:56:42
Open Price Low Price High Price Close Price Previous Close
1.92 1.87 1.995 1.99 1.93
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
11,410 4,091,654 US$ 1.94 US$ 7,924,866 - 1.68 - 3.84
Last Trade Type Quantity Price Currency
18:56:42 formt 510 US$ 2.00 USD

Geron Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.08B 543.06M - 596k -141.9M -0.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Geron News

Date Time Source News Article
11/28/202315:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/28/202315:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
11/28/202315:05Edgar (US Regulatory)Form 8-K - Current report
11/28/202307:00Business WireGeron Corporation Announces Appointment of Gaurav Aggarwal,..
11/16/202315:30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule..
11/07/202315:30Business WireGeron to Participate at Upcoming Investor Conferences in..
11/02/202316:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
11/02/202308:00Business WireGeron IMerge Phase 3 Presentations at Upcoming ASH Annual..
11/02/202307:50Edgar (US Regulatory)Form 8-K - Current report
11/02/202307:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202307:00Business WireGeron Corporation Reports Business Highlights and Third..
10/26/202315:30Business WireGeron to Announce Third Quarter 2023 Financial Results on..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GERN Message Board. Create One! See More Posts on GERN Message Board See More Message Board Posts

Historical GERN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.972.0351.851.933,112,2550.031.52%
1 Month1.762.071.681.884,772,1140.2413.64%
3 Months2.472.6551.681.975,492,934-0.47-19.03%
6 Months3.303.7351.682.525,541,920-1.30-39.39%
1 Year2.353.841.682.656,399,254-0.35-14.89%
3 Years1.873.840.98992.174,444,8510.136.95%
5 Years1.683.840.752.023,599,4930.3219.05%

Geron Description

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |